» Articles » PMID: 35520107

A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel

Abstract

Dry eye disease (DED) has a higher prevalence than many important systemic disorders like cardiovascular disease and diabetes mellitus, representing a significant quality of life burden for the affected patients. It is a common reason for consultation in general eye clinics worldwide. Nowadays, the diagnostic and therapeutic approach at the high corneal and ocular surface specialty level should be reserved for cases of severe and chronic dry eye disease associated with systemic autoimmune diseases or complicated corneal and ocular surface pathologies. In such cases, the diagnostic and therapeutic approach is often complex, elaborate, time-consuming, and costly due to the use of extensive dry eye questionnaires, noninvasive electronic diagnostic equipment, and clinical laboratory and ancillary tests. However, other eye care specialists attend a fair amount of DED cases; therefore, its diagnosis, classification, and management should be simple, practical, achievable, and effective. Considering that many patients attending non-specialized dry eye clinics would benefit from better ophthalmological attention, we decided to elaborate a practical DED classification system based on disease severity to help clinicians discriminate cases needing referral to subspecialty clinics from those they could attend. Additionally, we propose a systematic management approach and general management considerations to improve patients' therapeutic outcomes according to disease severity.

Citing Articles

Enhancing Ocular Surface in Dry Eye Disease Patients: A Clinical Evaluation of a Topical Formulation Containing Sesquiterpene Lactone Helenalin.

Ng D, Altamirano-Vallejo J, Navarro-Partida J, Sanchez-Aguilar O, Inzunza A, Valdez-Garcia J Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399390 PMC: 10892869. DOI: 10.3390/ph17020175.


The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease.

Munoz-Villegas P, Sanchez-Rios A, Olvera-Montano O Clin Ophthalmol. 2023; 17:2945-2955.

PMID: 37822327 PMC: 10563771. DOI: 10.2147/OPTH.S433709.


Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy.

Ruiz-Lozano R, Azar N, Mousa H, Quiroga-Garza M, Komai S, Wheelock-Gutierrez L Front Toxicol. 2023; 5:1067942.

PMID: 37547228 PMC: 10403269. DOI: 10.3389/ftox.2023.1067942.

References
1.
Robin J, Jester J, Nobe J, Nicolaides N, Smith R . In vivo transillumination biomicroscopy and photography of meibomian gland dysfunction. A clinical study. Ophthalmology. 1985; 92(10):1423-6. DOI: 10.1016/s0161-6420(85)33848-4. View

2.
Jacobi C, Jacobi A, Kruse F, Cursiefen C . Tear film osmolarity measurements in dry eye disease using electrical impedance technology. Cornea. 2011; 30(12):1289-92. DOI: 10.1097/ICO.0b013e31821de383. View

3.
Jones L, Downie L, Korb D, Benitez-Del-Castillo J, Dana R, Deng S . TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3):575-628. DOI: 10.1016/j.jtos.2017.05.006. View

4.
Papas E . The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021; 41(6):1254-1266. DOI: 10.1111/opo.12888. View

5.
Vitali C, Moutsopoulos H, Bombardieri S . The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis. 1994; 53(10):637-47. PMC: 1005429. DOI: 10.1136/ard.53.10.637. View